16 - Tolerance, Autoimmunity, and Transplantation Flashcards

1
Q

Antigen sequestration

A

tissue specific antigen that are expressed in certaint sites (like the anterior chamber and lese of the eye), are partially isolated from most lymphocytes and inflammatory mediators, and thereby evade the immune system.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Central tolerance

A

occurs in primary lymphoid organs, where many self.reactive lymphoctes are eliminated before they can mature, and others are selected (at least in the thymus) to later engage in immune inhibitory responses targetinf self-Ags at tissue sites, protecting against autoimmunity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

factors that promote tolerance rather than stimulation of the immun system by a given antigen

A
  • fetal exposure
  • high doses of Ag
  • Long-term persistence of Ag in the host
  • intravenous or oral introduction
  • absence of adjuvants
  • low levels of costimulation
  • presentation of Ag by immature or inactivated APCs
  • need for coordination between different immune cell types.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Peripheral tolerance

A

Peripheral tolerance processes occur after lymphocyte development, when immune cells are induced to act as inhibitors of self reactivity for Ag that is presented in a nonimmunogenic context.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Immune cells that inhibit immune responses against self

A

Tregs
Bregs

Treg cells, which inhibit immune reactivity against their cognate Ag int he periphery, can be CD4+ or CD8+, and typically express CD25 (IL-2R α chain), CTLA-4 (coinhibitory receptor), plus the master regulator TF FoxP3

Regulatory T cells dampen immune responses by inhibiting, decommissioning, or killing other immune cells that respond to their cognate Ag, including T cells, B cells and pAPCs. They do this through immune-suppressing cytokines (IL-10, TGF-β, IL-35), expression of inhibitory surface molecules (like CTLA-4), absorbing local IL-2 (with CD25), and via cellular cytotoxicity.

Regulatory populations og B cells (Bregs) and macrophages (MDSCs) can also suppress inflammation, often by secreting compounds like IL-10 and by acting as immune-inhibiting APCs.

MDSCs = myeloid-derived supressor cells.
Bregs have also been shown to supress inflammatory immune cascades associated with IL-1.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

B10 cells

A

B cells that produce only the cytokine IL-10. Suppress or regulate immune response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Hashimoto’s Thyroiditis

A

Organ specific

the individual produces Abs and sensitized TH! cells specific for thyroid antigens.

targeted proteins: thyroglobulin and thyroid peroxidase

Abs binding to these proteins interferes with iron uptake, leading to decreased thyroid function and hypothyroisism (decreased roduction of thyroid hormones).

Leads to organ destruction (lymphocytes, macrophages and plasma cells infiltrate), hypothyroidism and inflammatory accumulation. More common in women, no one knows exactly why

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Type 1 Diabetes

A

organ-specific

aka insulin dependent diabetes mellitis (IDDM)

caused by immune attack on insulin-producing cells (beta cells) in pancreas

the disease begins with cytotoxic T lymphocyte infiltration and activation of macrophages, which leads to cell mediated DTH response. results in cytokine release and the production of Abs.

most common therapy is daily administration of insulin to the affected individual.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Myasthenia Gravis

A

Tissue specific

mediated by blocking Abs.

produces auto-Abs that bind Acetyl-Choline (a neurotransmitter) receptors (AChR) on the motor end plates of muscles, blocking normal binding og acetylcholine, resulting in progressive weakening of the skeletal muscles. Abs cause the lysis of the cells bearing the receptors.

treatment: increasing acetylcholine levels, decreasing Ab production, removing Abs.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Systemic lupus erythematosus

A

SLE, lupus

while-body autoimmune disease.

results from Abs against common cellular components (DNA, histones, platelets ++), leading to Type III Hypersensitivity with immune complexes blocking blood vessels, and ultimately progressive organ failiure.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Multiple sclerosis

A

a neurologic autoimmune siease caused by autoreactive T cells that rec components of the CNS, leading to the desrtuction of the myelin sheath surrounding nerves and progressive neurological dysfunction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Rheumatoid arthritis

A

systemic autoimmune disease that usually develops later in life, caused by Abs against cotrullinated protein Ags ant the Fc resion og IgG (called the rheumatoid factor), leading to immune complex deposition in joints and progressive joint destruction via complement.

Defects in AIRE and FoxP3 genes can lead to systemic syndromes (APS-1 and IPEX, respectively) affecting a myriad of Ags, manifesting both autoimmune and immune deficiency-like symptoms, all due to disruption to Treg cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Potential causes for autoimmunity (genetic, envorinmental, certains T helper cell types)

A

Genetic: genetic variants of one or more immune-related genes are associated with predisposition to most autoimmune diseases, most notably certain MHC alleles and immune-regulatory genes (e.g., AIRE and FoxP3).

Enviromental: Envorinmental factors, like diet, obesity, smoking, infection, and mucosal microflora, all have been associated with risk of autoimmune diseases, typically if the individual already are susceptible genetically.

T helper cells: TH17 cells, along with the cytokines they produce (IL-17 and IL-23), are linked to several autoimmune diseases in animal models and humans.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Treatments for autoimmune diseases (list)

A

3 main strategies:

1) broad-spectrum immunosupressive treatmens
2) immunosupression directed at specific cells or pathways
3) targeted immunotherapy aimed at guiding the host immune cells toward a new and more beneficial pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Broad-spectrum immunotherapies

A

broad-spectrum immune suoressants.

Not cures, just relief from symptoms, providing the patient with acceptible quality of life

examples: corticosteroids and methotrexate.

supress lymphocytes indiscriminantly, inhibiting their survival and proliferation, or by killing those who rapidly divide.

side effects: general cytotoxicity, increased risk of uncontrolled infection, increased risk of cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Immunosupression targeted at specific cell types

A

if Abs and/or immune complexes are heavily involved in autoimmune pathology, strategies aimed at killing or blocking B cells can improve symptoms. However, in most cases T cells also need to be targeted, as they are the cells that are either directly pathogenic or provide help for autoreactive B cells.

Attempts have been made of targeting CD3 and CD4 on T cells, but with little efficacy. The transfer of Tregs can inhibit diease in mouse models

17
Q

Therapies that block specific steps in the inflammatory process of autoimmunity

A

depending on the relevant cell type or cytokine, therapies that block B cells, T cells, specific pathways, and subsets of cells or their products have shown some promise in the treatment of specific autoimmune diseases.

18
Q

Blocking costimulation as a treatment for autoimmunity

A

A CTLA-4Ig fusion protein (CTLA-4 + IgG1) is designed to block CD80/86 on APCs from engaging with CD28 on T cells, inhibiting costimulation.

Limited success with MS and IBD, low success in lupus.

19
Q

Ag-specific immunotherapy

A

Treatment for autoimmune disease that induces tolerance for the auto-Ags in question and/or redirects the damaging effector response away from its target without impacting other immune processes would be ideal, but it is still in its investigational stages.

20
Q

Different types of transplants

A

Autograft: self-tissue transferred from one body site to another in the same individuals

Isograft: tissue transferred between genetically identical individuals, as with identical twins or an inbred strain of mice, when the donor and recipient are syngenetic.

Allograft: Tissue transferred between genetically differnt members of the same species. This is the most common type of tissue graft, ocurring between nonidentical humans or different strains of mice.

Xenograft: tissue transferred between different species.

Auto- and isografts are usually accepted (due to genetic identity)

Tissues that share sufficient antigenic similarity to allow transfer without rejection are histocompatible.

21
Q

Three important pre-transplantation tests

A

1) Blood-group matching.
the first human kidney transplant failed due to differnt blood types in donor and recipient.

2) MHC matching (aka tissue typing)
MHC compatibility. If MHC is very important, usually family members (siblings/parents) are the donors. Most rigous MHC testing is conducted in bone marrow translplant, where at least partial HLA matching is crucial to ensure that grafted immune cells like APCs and T cells will be able to rec MHC alleles in the new host.

tissue typing = the serologic or molecular tests that determine HLA compatibility.

If MHC alleles are identical, minor histocompability locus must also be compatible, otherwise the result can be rejection. Therefore, some levels of immunosuppression is usually still needed even if the HLA-identical matches.

3) cross-matching
the presence of any preformed Abs against potential donor alloantigens (present in some but not all individuals in a species) can fuck up a transplant. previos reception of blood or grafts may cause them. Positive cross-matching = bad.

22
Q

Types of graft rejection

A

hyperacute

acute rejection

chronic

23
Q

Hyperactute graft rejection

A

wihtin hours, caused by damage of the transplanted capillaries by preformed Abs recognizing foreign Ags, including those from ABO and HLA.

Steps:

1) Pre-existing host Abs are carried to kidney graft
2) Abs bind to Ags of renal capillaries ad activate complement
3) Complement split products attract neutrophils, which release lytic enzymes
4) Neutrophil lytic enzymes destroy endothelial cells; platelets adhere to injured tissue, causing vascular blockage

24
Q

acute graft rejection

A

induced by T cells (esp CD4+), APCs, and their cytokines after an initial sensitization to donor alloantigens via either direct or indirect presentation to host T cells, leading to inflammation and cell death, usually weeks or months after transplantation.

2 stages: sensitization phase and effector phase.
1) sensitization phase: CD4+ and CD8+ T cells rec alloantigens expressed on the foreign graft, proliferate in response. both minor and major histocompatibility alloantigens can be recognized.
The response to MHC Ags can involve recipient T cells recognizing donor MHC molecules expressed on the surface of cells in the transplant (direct presentation), or recognize processed peptides from donor HLA proteins via self-MHC (indirect presentation).

2) effector phase
hallmark: large influx of leukocytes (esp CD4+ and macrophages)

leukocytes, cytokines (IL-2, IFN-y), APCs

25
Q

chronic graft rejection

A

can occur months to years after resolution of earlier rejection responses, follows the same course as acute rejection, has unknown inducers, and is more resistant to reversal by standatd immunosuppression.

26
Q

graft vs host disease

A

GvHD
the introduction of immunocompetend cells from a foreign donor means that the transplant can attack host alloantigens, or foreign MHC molecules present on recipient tissues.

treating the patient with x-rays (total lymphoid irradiation to eliminate lymphocytes) can be used to treat this.

27
Q

Total lymphoid irradiation to eliminate lymphocytes

A

lymphocytes are extremely sensitive to x rays. The recipient of a graft can be treated with multiple x-ray exposures to the thymus, spleen, and lymph nodes before the transplant. not part of many transplant procedures, but normal before bone marrow or HSC transplantation.

because the bone marrow is not exposed to the rays, lymphoid stem cells proliferate and renew the population of recirculatoing lymphocytes. These are more likely to be tolerant of the graft.

Used to treat GvHD.

28
Q

Generalized immunosupressive therapy (transplantation)

A

Azathioprine is a potent mitotic inhibitor, often given just before and after transplantation to diminish both B- and T cell proliferation.

Cyclophosphamide insetrs into the DNA helix and becomes cross-linked, leading to disruptions of the DNA chain, and is especially effective against rapidly dividing cells, like proliferating T cells. given at the time of grafting to block T cell proliferation.

mitotic inhibitors act on all cells, and therefore have side effects (esp affecting gut and liver). They are often given with croticosteroids, with suppress immune responses by repressinf NF-kB (essential for the induction of many immune genes, like cytokines, that are involved in graft rejection)

29
Q

Specific immunosupressive therapy (transplantation)

A

try to be Ag-specific, limit the immune response to the graft/alloantigens but still retain the ability to react to al other foreign antigens.

monoclonal Abs are important for this, soluble ligands that bind specific cell-surface molecules.

Limitation: usually from animals, meaning that the recipient will have an immune response against them.
this can be overcome by humanizing mAbs.

Many mAbs have been tested in transplantation setting, the majority work by either depleting the recipient of a particular cell population or by blocking a key step in immune signalling.

mAbs can target costimualtion, specific cytokines, or certain immune cell types for destruction.

30
Q

two situations that favor allografts

A

1) when cells or tissue are grafter to a “priviledged” site that is more protected from immune system surveilance

2) when a state of tolerance to donor alloantigens has been induced biologically in the recipient prior to transfer.
Ex: non-MZ twins that share a placenta.

31
Q

Immunologically privileged sites

A

sites: f.ex. anterior chamber of eye, cornea, uterus, testes, and brain
All have few lymphatic vessels, some also few blood vessels.

32
Q

Cells and cytokines associated with graft tolerance

A

FoxP3, Tregs.

Tregs inhibit alloreactive cells by a combination of direct contact and expression of immunosupressive cytokines (like TGF-β, IL-10 and IL-35).

33
Q

Inducing transplantation tolerance

A

current favorite:
involves the induction of a state of mixed hemotopoietic chimerism, where donor and recipient hematopoietic cells coexist in the host prior to transplantation.

Transplant recipients who underwent total myeloblative therapy followed by donor bone marrow transfer prior to recieveing a solid organ from the same donor displayed enhanced later tolerance.

a less intense nonmyeloablative procedure followed by bone marrow transfer resulted in mixed chimerism that, even when quite transient, was still associated with improved graft outcomes.